Brucella melitensis and Human Brucellosis

Brucella melitensis belongs to the family Brucellaceae within the class Alphaproteobacteria. It is a small Gram-negative coccobacillus that typically appears singly or in pairs under microscopy.

The bacterium is non-motile, lacks flagella, and does not form spores. It is an obligate aerobic organism with relatively fastidious nutritional requirements and grows slowly in laboratory culture, often requiring several days to weeks to form small, translucent colonies.

A defining biological feature of B. melitensis is its facultative intracellular lifestyle. After entering the host, the organism can survive and replicate within macrophages and other phagocytic cells. This intracellular persistence enables immune evasion and contributes to the chronic nature of brucellosis.

Sheep and goats serve as the primary natural reservoirs of Brucella melitensis. Infected animals may exhibit reproductive disorders such as abortion, infertility, or orchitis. However, many animals remain asymptomatic carriers that continue to shed bacteria.

The pathogen can be excreted in milk, vaginal secretions, semen, feces, and aborted fetal tissues, leading to environmental contamination and transmission to humans.

Human infection typically occurs through several routes:

• Direct contact: Occupational exposure during animal handling, veterinary procedures, or slaughtering activities allows bacterial entry through damaged skin or mucous membranes.
• Foodborne transmission: Consumption of unpasteurized dairy products or inadequately cooked contaminated meat.
• Aerosol inhalation: Exposure to contaminated aerosols in laboratory environments or livestock facilities.

Human infection with B. melitensis results in brucellosis, a systemic disease with a typical incubation period of one to four weeks, although longer latency periods have been documented.

Acute Stage: Patients often develop undulating fever characterized by intermittent episodes of fever separated by afebrile periods. Additional symptoms may include night sweats, fatigue, headache, and musculoskeletal pain. Hepatosplenomegaly and lymphadenopathy are also frequently observed.

Chronic Stage: Without appropriate treatment, the infection may become chronic, presenting with persistent low-grade fever, prolonged fatigue, and multi-organ involvement. Complications may include osteoarticular infections, spondylitis, endocarditis, orchitis, and neurological manifestations.

Because clinical symptoms are often nonspecific, brucellosis can be misdiagnosed as influenza, rheumatologic disorders, or tuberculosis.

Diagnosis relies on the integration of epidemiological history, clinical symptoms, and laboratory testing.

Serological methods such as the Rose Bengal test and tube agglutination tests are commonly used for screening and diagnostic evaluation.

Isolation of the bacterium from blood, bone marrow, or other clinical specimens remains the laboratory gold standard. However, culture procedures are time-consuming and require biosafety precautions due to the infectious nature of the organism.

Molecular diagnostic methods, including probe-based real-time PCR assays, provide rapid and specific detection of pathogen DNA and are valuable for early identification in clinical or surveillance settings.

Treatment of brucellosis is challenging due to the intracellular persistence of B. melitensis. Effective therapy requires antimicrobial agents capable of penetrating host cells.

Incomplete treatment is associated with relapse or chronic infection, emphasizing the importance of adequate duration and combination therapy.

Brucella melitensis remains a significant zoonotic pathogen affecting both livestock and human populations in endemic regions. Its intracellular survival strategy and chronic disease course present challenges for diagnosis and treatment.

Effective control strategies depend on integrated veterinary and public health approaches, including livestock vaccination, surveillance of animal populations, and safe food production practices. Improved diagnostic technologies and coordinated disease monitoring are essential for reducing the burden of brucellosis worldwide.